Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1975 1
1976 1
1977 1
1979 2
1980 6
1981 6
1982 4
1983 2
1984 4
1985 5
1986 6
1987 11
1988 18
1989 38
1990 31
1991 29
1992 37
1993 39
1994 34
1995 58
1996 50
1997 43
1998 50
1999 43
2000 72
2001 58
2002 71
2003 90
2004 76
2005 86
2006 99
2007 84
2008 90
2009 103
2010 134
2011 130
2012 132
2013 159
2014 179
2015 180
2016 224
2017 281
2018 235
2019 280
2020 354
2021 427
2022 454
2023 462
2024 195

Text availability

Article attribute

Article type

Publication date

Search Results

4,682 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for anti tau
Search for Anqi Tan instead (3 results)
[Anti-tau therapies-what can be expected?].
Fließbach K, McCormick C, Kaulen B, Schneider A. Fließbach K, et al. Nervenarzt. 2019 Sep;90(9):891-897. doi: 10.1007/s00115-019-0758-7. Nervenarzt. 2019. PMID: 31332452 Review. German.
Alzheimer's disease is histopathologically characterized by aggregation of two proteins, namely amyloid-beta peptide and tau protein. Whereas former intervention trials focused particularly on the amyloid pathology, recent therapeutic approaches are directed against the …
Alzheimer's disease is histopathologically characterized by aggregation of two proteins, namely amyloid-beta peptide and tau protein. …
Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models.
Krishnaswamy S, Huang HW, Marchal IS, Ryoo HD, Sigurdsson EM. Krishnaswamy S, et al. Neurobiol Dis. 2020 Apr;137:104770. doi: 10.1016/j.nbd.2020.104770. Epub 2020 Jan 23. Neurobiol Dis. 2020. PMID: 31982516 Free PMC article. Review.

Control flies not expressing htau survived the longest, whereas R406W expressing flies had the shortest lifespan, which was greatly prolonged by co-expressing the anti-tau scFv (p < .0001). Likewise, htau WT expressing flies had a moderately short lifespan, which

…
Control flies not expressing htau survived the longest, whereas R406W expressing flies had the shortest lifespan, which was greatly prolonge …
Alzheimer's disease: Recent treatment strategies.
Vaz M, Silvestre S. Vaz M, et al. Eur J Pharmacol. 2020 Nov 15;887:173554. doi: 10.1016/j.ejphar.2020.173554. Epub 2020 Sep 15. Eur J Pharmacol. 2020. PMID: 32941929 Review.
Currently, most anti-tau agents in clinical trials are immunotherapies and they are in the early stages of clinical research. Four monoclonal antibodies anti-tau (Gosuranemab, Tilavonemab, Semorinemab and Zagotenemab) and one anti-tau vac …
Currently, most anti-tau agents in clinical trials are immunotherapies and they are in the early stages of clinical research. …
Effectiveness and safety of anti-tau drugs for Alzheimer's disease: Systematic review and meta-analysis.
Zheng X, Tang Y, Yang Q, Wang S, Chen R, Tao C, Zhang P, Fan B, Zhan J, Tang C, Lu L. Zheng X, et al. J Am Geriatr Soc. 2022 Nov;70(11):3281-3292. doi: 10.1111/jgs.18025. Epub 2022 Oct 8. J Am Geriatr Soc. 2022. PMID: 36208415 Review.
DISCUSSION: Current evidence suggests that anti-tau drugs are unlikely to have an important impact on slowing cognitive impairment. ...Additional large-scale and well-designed randomized and placebo-controlled trials will be necessary to explore the benefit of a cer …
DISCUSSION: Current evidence suggests that anti-tau drugs are unlikely to have an important impact on slowing cognitive impair …
Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?
Del Giudice KP, Cosgaya M, Zaro I, Ravasi V, Santacruz P, Painous C, Fernández M, Cámara A, Compta Y. Del Giudice KP, et al. Parkinsonism Relat Disord. 2024 Mar 8:106080. doi: 10.1016/j.parkreldis.2024.106080. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 38508903 Review.
Already completed clinical trials have ranged from initially negative results to recently partial positive outcomes, specifically for anti-amyloid antibodies in AD but also albeit to lesser degree for anti-synuclein antibodies in PD. Currently, there are several ong …
Already completed clinical trials have ranged from initially negative results to recently partial positive outcomes, specifically for ant …
Central and peripheral tau retention modulated by an anti-tau antibody.
Solorzano A, Brady M, Bhatt N, Johnson A, Burgess B, Leyva H, Puangmalai N, Jerez C, Wood R, Kayed R, Deane R. Solorzano A, et al. bioRxiv [Preprint]. 2023 Aug 18:2023.08.17.553682. doi: 10.1101/2023.08.17.553682. bioRxiv. 2023. PMID: 37645819 Free PMC article. Preprint.
Near infrared fluorescence (NIRF) was mainly used to analyze tau (tau-NIRF) distribution after its intracisternal or intravenous injection. ...The presence of tau in the bladders suggested excretion routes of tau. CSF anti-tau antibody in …
Near infrared fluorescence (NIRF) was mainly used to analyze tau (tau-NIRF) distribution after its intracisternal or intraveno …
Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease.
Kayed R. Kayed R. Hum Vaccin. 2010 Nov;6(11):931-5. doi: 10.4161/hv.6.11.12689. Epub 2010 Nov 1. Hum Vaccin. 2010. PMID: 20980799 Review.
The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer's disease (AD) and many neurodegenerative diseases. ...Tau intermediate aggregate (tau oligomers; aggregates of an intermediate that is betwee …
The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer's disease (AD) a …
Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies.
Rodrigues Martins D, Sha F, Van der Elst W, Shih PY, Devoght J, Van Kolen K, Mercken M, Van Broeck B, Declerck P, Theunis C. Rodrigues Martins D, et al. Mol Ther Methods Clin Dev. 2023 Nov 14;31:101158. doi: 10.1016/j.omtm.2023.101158. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 38074413 Free PMC article.
As such, we engineered three anti-tau monoclonal antibodies into single-chain variable fragments for cytoplasmic expression and activity: PT51, PT77, and hTau21. ...Collectively, our work extends the current knowledge on intracellular tau targeting with intra …
As such, we engineered three anti-tau monoclonal antibodies into single-chain variable fragments for cytoplasmic expression an …
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy.
Colin M, Dujardin S, Schraen-Maschke S, Meno-Tetang G, Duyckaerts C, Courade JP, Buée L. Colin M, et al. Acta Neuropathol. 2020 Jan;139(1):3-25. doi: 10.1007/s00401-019-02087-9. Epub 2019 Nov 4. Acta Neuropathol. 2020. PMID: 31686182 Free PMC article. Review.
Finally, such new ways of thinking have led to different therapeutic strategies in anti-tau immunotherapy among tauopathies and have stimulated new clinical trials. ...From this review, it appears that further studies are needed (1) to characterize extracellular …
Finally, such new ways of thinking have led to different therapeutic strategies in anti-tau immunotherapy among tauopathies an …
4,682 results